Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab and Pembrolizumab in Metastatic Colorectal Cancer
NCT02713373Phase 2Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Aug 2016
- Primary completion
- Jul 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and KL-140 in colorectal cancer (CRC), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoints: Adverse Event Profile at 24 months, Progression-Free Survival at 6 months and 1 more. Started Aug 2016; status: completed.
02
Drugs
pembrolizumabKL-140
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02713373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02713373.